HomeSGX-LISTED COMPANIESLincotrade & Associates Holdings Limited: FY2025 Financial Announcement

Lincotrade & Associates Holdings Limited: FY2025 Financial Announcement

Published on

spot_img

Lincotrade’s latest financial announcement highlights a period of significant growth and strategic reorientation. The company experienced an overall improvement in performance, largely attributed to a sharpened focus on its commercial segment, which features higher-margin projects. This period also saw notable diversification, with new investments in property development and expansion into international markets, alongside key operational developments aimed at enhancing future capabilities.

• The company’s strategic shift towards securing specific types of projects has significantly bolstered its financial outcomes

• New ventures and geographical expansions are actively contributing to a broader business footprint and new revenue streams

• Major operational changes, including facility upgrades and asset reconfigurations, signal evolving capabilities for the upcoming periods

LISTEN TO THE PODCAST BELOW:

Latest articles

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...

AstraZeneca deploys AI to cut drug timelines by 30% and boost survival

AstraZeneca is stepping up its investment in AI drug discovery to shorten treatment timelines...

More like this

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...